International Assets Investment Management LLC Makes New Investment in IQVIA Holdings Inc. (NYSE:IQV)

International Assets Investment Management LLC purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the 4th quarter, Holdings Channel reports. The fund purchased 59,465 shares of the medical research company’s stock, valued at approximately $13,759,000.

Other institutional investors have also recently modified their holdings of the company. AMF Tjanstepension AB purchased a new stake in shares of IQVIA during the 3rd quarter worth $148,096,000. Eagle Asset Management Inc. acquired a new stake in shares of IQVIA in the third quarter valued at about $102,982,000. iA Global Asset Management Inc. boosted its holdings in IQVIA by 1,225.3% during the third quarter. iA Global Asset Management Inc. now owns 320,271 shares of the medical research company’s stock worth $63,013,000 after buying an additional 296,105 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its holdings in IQVIA by 2,765.6% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 271,316 shares of the medical research company’s stock valued at $53,381,000 after buying an additional 261,848 shares in the last quarter. Finally, Qube Research & Technologies Ltd purchased a new position in IQVIA in the third quarter valued at about $47,282,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Ari Bousbib sold 31,678 shares of the company’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the completion of the sale, the insider now directly owns 796,752 shares in the company, valued at approximately $199,610,278.56. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, insider Ari Bousbib sold 31,678 shares of the business’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the completion of the sale, the insider now owns 796,752 shares in the company, valued at approximately $199,610,278.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kevin C. Knightly sold 8,607 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the completion of the transaction, the insider now owns 5,251 shares in the company, valued at approximately $1,313,642.67. The disclosure for this sale can be found here. Insiders have sold a total of 41,285 shares of company stock valued at $10,331,003 over the last quarter. Company insiders own 1.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Evercore ISI lowered their price target on IQVIA from $275.00 to $250.00 and set an “outperform” rating on the stock in a report on Friday. BTIG Research initiated coverage on shares of IQVIA in a research note on Tuesday, February 13th. They issued a “buy” rating and a $285.00 price objective on the stock. Robert W. Baird cut their target price on shares of IQVIA from $254.00 to $245.00 and set a “neutral” rating for the company in a research report on Friday. SVB Leerink initiated coverage on shares of IQVIA in a research note on Monday, February 26th. They set an “outperform” rating and a $290.00 price objective for the company. Finally, UBS Group upped their target price on IQVIA from $240.00 to $300.00 and gave the company a “buy” rating in a research note on Thursday, February 15th. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $257.57.

IQVIA Stock Performance

IQVIA stock opened at $223.37 on Friday. The stock has a fifty day moving average price of $244.08 and a 200 day moving average price of $224.01. IQVIA Holdings Inc. has a 52 week low of $167.42 and a 52 week high of $261.73. The firm has a market capitalization of $40.54 billion, a P/E ratio of 30.52, a PEG ratio of 2.15 and a beta of 1.52. The company has a current ratio of 0.88, a quick ratio of 0.86 and a debt-to-equity ratio of 2.02.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.84 EPS for the quarter, beating analysts’ consensus estimates of $2.82 by $0.02. IQVIA had a net margin of 9.01% and a return on equity of 29.17%. The company had revenue of $3.87 billion during the quarter, compared to the consensus estimate of $3.80 billion. During the same quarter in the prior year, the company posted $2.54 EPS. The company’s quarterly revenue was up 3.5% compared to the same quarter last year. Equities research analysts anticipate that IQVIA Holdings Inc. will post 10.12 earnings per share for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.